MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14760584.2023.2234997

Медицинская библиотека · Expert review of vaccines · 2023

Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trial.

Wu Yan-Fei, Wei Ming-Wei, Wang Rui-Jie, Guo Xi-Ling, Pan Hong-Xing, Gao Ya-Chun, Li Xiao-Long, Wang Xue, Ma Xiao-Min, Wan Peng, Zhou Li, Zhu Ya-Wen, Li Jing-Xin, Zhu Feng-Cai

Рандомизированное исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

The certification of immunogenicity consistency at different production scales is indispensable for the quality control of vaccines.

RESEARCH DESIGN AND

METHODS

A randomized, double-blind immunobridging trial in healthy adults aged 18-59 was divided into Scale A (50 L and 800 L) and Scale B (50 L and 500 L) based on vaccine manufacturing scales. Eligible participants in Scale A were randomly assigned to receive the single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) of different scales at a 1:1 ratio, as was Scale B. The primary endpoint was the geometric mean titer (GMT) of anti-live SARS-CoV-2-specific neutralizing antibodies (NAb) 28 days post-vaccination.

RESULTS

1,012 participants were enrolled, with 253 (25%) per group. The post-vaccination GMTs of NAb were 10.72 (95% CI: 9.43, 12.19) and 13.23 (11.64, 15.03) in Scale A 50 L and 800 L, respectively; 11.64 (10.12, 13.39) and 12.09 (10.48, 13.95) in Scale B 50 L and 500 L, respectively. GMT ratios in Scale A and B have a 95% CI of 0.67-1.5. Most adverse reactions were mild or moderate. 17 of 18 participants reported non-vaccination-related serious adverse reactions.

CONCLUSIONS

The Ad5-nCoV in the scale-up production of 500 L and 800 L showed consistent immunogenicity with the original 50 L production scale, respectively.

Для цитирования: Wu Yan-Fei, Wei Ming-Wei, Wang Rui-Jie, Guo Xi-Ling, Pan Hong-Xing, Gao Ya-Chun, Li Xiao-Long, Wang Xue, Ma Xiao-Min, Wan Peng, Zhou Li, Zhu Ya-Wen, Li Jing-Xin, Zhu Feng-Cai. Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trial.. Expert review of vaccines. 2023. DOI: 10.1080/14760584.2023.2234997.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.